The results of research of reactogenity and immunologic efficacy of hepatitis A and B with purified concentrated adsorbed liquid "HEP-A+B-in-VAC" vaccine

This paper makes an appraisal of the immunological efficiency of the Vector-BiAlgam vaccine by testing the protective antibodies in comparison with instant introduction of monovaccine against hepatitis A and B. Also the reactogenity qualities of the vaccine when thrice repeated was evaluated. Results show that the local reactions in majority of the subjects manifested within a short time. The number of reactions in the experimental group at different stages of vaccination varied from 20.3 to 36.3%. By means of comparative analysis it was found that the general and local reactions in the control group were registered more often, although the reactions qualitatively were not different. For the vaccinated group, the reactions with the divaccine were slightly expressed and of short duration. Post vaccinal complications in both groups were not found. The research results of the immune qualities of divaccine "HEP-A+B-in-VAC" were positive: the percentage of seroconversions after three vaccinations was 100%. The great majority of the volunteers of the experimental group had 72.2% protective antibodies to the HBs-antigen that formed with a high titer (more than 1000 UI/L). High titers of antibodies to the hepatitis virus A were determined among 90.9% volunteers. In the control group after three vaccinations, seroconversion occurred among 100% of the vaccinated subjects. In conclusion, the received results of a newly elaborated hepatitis A and B "HEP-A+B-in-VAC" vaccine is the evidence of a weak reactogenity and a high immune activity.